Please select the option that best describes you:
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
Answer from: Medical Oncologist at Academic Institution
The IMbrave050 showed that the combination atezolizumab/bevacizumab improved recurrence free survival in high risk resected HCC patients with RFS 78% vs 65% at 12 months, HR 0.72 (95% CI 0.56, 0.93), this tapered off at approximately 24 months. This suggests that the combination delayed recurrence a...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Not convinced based on this early report. I will wait to see longer RFS results given curved coming together and small benefits (borderline significant). OS is the real metric we need to see here.
UPDATE 2025. The last presentation at ESMO 2024 showed a slightly inferior PFS for the treatment...
Answer from: Medical Oncologist at Community Practice
Please note, this was a negative trial in the end and even potentially harmful (Yopp et al., Annals of Oncology 2024), and notes the importance of waiting for final data before acting on early signals.
Answer from: Medical Oncologist at Academic Institution
Update 4/7/25: Updated results for IMbrave050 were presented at ESMO 2024 and indicated no significant improvement in OS. A small percent (7%) continued to derive an RFS benefit. This has to be considered with the AE profile- with 9% of patients discontinuing treatment due to a TRAE. The updates con...
Answer from: Medical Oncologist at Academic Institution
The phase 3 randomized adjuvant Atezo/Bev IMbrave050 study (Hack et al., PMID 32352320) in HCC reached its primary endpoint of improving recurrence free survival and once approved by regulatory bodies based on their current data review in the US and globally, it will set a new standard of care optio...